cericlamine cericlamine cericlamine (inn; developmental code jo-1017) is a potent and moderately selective serotonin reuptake inhibitor (ssri) of the amphetamine family (specifically, a derivative of phentermine, and closely related to chlorphentermine, a highly selective serotonin releasing agent) that was investigated as an antidepressant for the treatment of depression, anxiety disorders, and anorexia nervosa by jouveinal but did not complete development and was never marketed. it reached phase iii clinical trials in 1996 before development was discontinued in 1999. cericlamineclinical dataroutes ofadministrationoralatc codenonepharmacokinetic dataelimination half-life8 hoursidentifiers iupac name 3-(3,4-dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol cas number112922-55-1pubchem cid131074chemspider115890uniives82d23ibchemical and physical dataformulac12h17cl2nomolar mass262.17 g·mol−13d model (jsmol)interactive image smiles cc(cc1=cc(=c(c=c1)cl)cl)(co)n(c)c inchi inchi=1s/c12h17cl2no/c1-12(8-16,15(2)3)7-9-4-5-10(13)11(14)6-9/h4-6,16h,7-8h2,1-3h3key:fwyrghmkhzxxqx-uhfffaoysa-n synthesis revised patent: orig patent: asymmetric: arylation of methacrylic acid with a diazonium salt of 3,4-dichloroaniline (or 3,4-dichloro-benzenediazonium salt), is carried out according to the meerwein reaction catalysed by a metallic halide. for the next step, the halide is displaced by dimethylamine, then esterification is performed, followed by reduction with a metal hydride.